| http://www.w3.org/ns/prov#value | - ???The ASCEND-HF trial has answered many scientific questions and has increased our understanding of the safety profile of NATRECOR??,??? said Peter M. DiBattiste, M.D., Vice President of Cardiovascular Development at Johnson & Johnson Pharmaceutical Research and Development, L.L.C. ???This is the largest trial ever conducted in patients with ADHF, and affirms our commitment to patients and physic
|
